entertainment -WSS

entertainment

author：fashion 2025-10-01 21:33:47 - browse：85322

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： ER docs worry over extreme heat as a 'mass casualty event'

explore

WSS

Pharma budget tightening trickles down to Doximity

White House drug shortages task force keeps mum with Congress

A look at other Americans who have crossed into North Korea over the years

Biden administration sends mixed signals on US soldier who crossed into North Korea

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Robert Kennedy Jr.'s presidential campaign attracts GOP

focus

entertainment

Wikipedia

How to save PrEP access — and even expand it

After John Oliver segment, STAT readers share their opioid

Cancer drug shortages should be causing more outrage

Covid's long

State Dept. review finds Biden bears some blame for Afghanistan failures

Timeline: Special counsel's investigation into Trump's handling of classified documents

The cancer drug shortage isn’t new — and neither are the solutions

White House drug shortages task force keeps mum with Congress

Affirmative action in medical school literally saved lives

GOP presidential candidates start declaring their loyalty

hotspot

A Theranos scientist

A Theranos scientist

After John Oliver segment, STAT readers share their opioid

Large hospital system sues Multiplan for low

Newly revealed memo details efforts to keep Trump in power following election loss

ER docs worry over extreme heat as a 'mass casualty event'

hotspot

explore

leisure time

hotspot